Targeting Neuropeptide Y/DPP4 Signalling Suppresses Ewing Sarcoma Survival and Improves Monocyte Viability
Open Access
- 17 March 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2731
Abstract
Survival rates for metastatic Ewing sarcoma (EwS) have remained persistently low over recent decades, highlighting the need for more effective chemotherapeutic options. Potential targets may be found within the Neuropeptide Y (NPY) signalling pathway that has been implicated in EwS cell survival. However, confounding factors include hypoxia that modulates NPY signalling, dipeptidyl peptidase-4 (DPP4/CD26) that cleaves NPY and interactions via NPY signalling from infiltrating immune cells. We investigated these interactions in A673 and SK-ES-1 EwS cell lines and THP-1 monocytes to identify therapeutic targets suitable for drug repurposing. Both EwS cell lines secreted NPY into conditioned media and extracellular vesicles. Recombinant NPY enhanced viability of both A673 and SK-ES-1 cells; however, the NPY1R antagonist BMS-193885 reduced viability in A673 cells only. Recombinant DPP4 widely promoted EwS viability and, under hypoxic conditions, it increased cell metabolism. The DPP4 inhibitor linagliptin, which is used clinically, consistently suppressed EwS viability with elevated sensitivity under hypoxia, where there was increased cell death of SK-ES-1 cells. Conversely, in THP-1 monocytes, NPY suppressed metabolism, BMS-193885 increased live-cell staining and DPP4 induced cell death. These findings suggest that NPY and DPP4 enhance EwS survival through autocrine/paracrine signalling while reducing monocyte viability. Thus, targeting the NPY/DPP4 signalling axis may provide therapeutic benefit by directly suppressing EwS growth and enhancing efficacy of immunotherapy.Keywords
All Related Versions
Funding Information
- Children’s Cancer and Leukaemia Group and Little Princess Trust Project Grant (CCLGA 2020 15)
This publication has 46 references indexed in Scilit:
- Decoding the immune landscape in Ewing sarcoma pathogenesis: The role of tumor infiltrating immune cells and immune milieuJournal of Bone Oncology, 2025
- Expression of hypoxia inducible factor–dependent neuropeptide Y receptors Y1 and Y5 sensitizes hypoxic cells to NPY stimulationJournal of Biological Chemistry, 2022
- NPY promotes macrophage migration by upregulating matrix metalloproteinase‐8 expressionJournal of Cellular Physiology, 2020
- Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma—Associations with tumor phenotype and survivalCancer, 2014
- Incidence and survival of malignant bone sarcomas in England 1979–2007International Journal of Cancer, 2011
- Higher Serum DPP-4 Enzyme Activity and Decreased Lymphocyte CD26 Expression in Type 1 DiabetesPathology and Oncology Research, 2011
- Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y1 receptor antagonistEuropean Journal of Pharmacology, 2008
- DPP4 Inhibitors: a new approach in diabetes treatmentAdvances in Therapy, 2008
- A pragmatic approach to the analysis of DNA histograms with a definable G1 peakCytometry, 1987
- Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in manLife Sciences, 1987